Aarti Pharma Labs Share Price | Aarti Pharma Labs Stock Screener
AARTIPHARM
Pharmaceuticals
Share Price NSE
₹701.30
▼
-10.45 (-1.47%)
Share Price BSE
₹701.05
▼
-13.75 (-1.92%)
As of May 18, 2026, the Aarti Pharma Labs share price (NSE: AARTIPHARM) is ₹701.30 on NSE and ₹701.05 on BSE, down 1.47% from the previous close, with shares trading between ₹687.05 and ₹707.90, and a 52-week range of ₹591.95–₹964.90.
Check Aarti Pharma Labs 52-week for the annual price range and momentum.
Use the Aarti Pharma Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Aarti Pharma Labs Market Cap
₹6,452.57 Cr.
AARTIPHARM P/E Ratio (TTM)
30.49
Aarti Pharma Labs P/B Ratio
3.18
EPS (TTM)
₹30.06
Dividend Yield
0.70%
Debt to Equity
0.19
AARTIPHARM 52 Week High
₹964.90
Aarti Pharma Labs 52 Week Low
₹591.95
Operating Margin
23.00%
Profit Margin
10.98%
AARTIPHARM Revenue (TTM)
₹437.00
EBITDA
₹104.00
Net Income
₹48.00
Total Assets
₹2,906.00
Total Equity
₹1,990.00
Aarti Pharma Labs Share Price Chart
Screen Aarti Pharma Labs share price with an interactive chart. Analyse AARTIPHARM price trends and volatility across different timeframes.
Aarti Pharma Labs Company Profile - Fundamental Screener
Screen Aarti Pharma Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AARTIPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0LRU01027
Aarti Pharma Labs Balance Sheet Screener
Screen AARTIPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 2,906 | 2,582 | 2,244 | 2,040 | 0 |
| Current Assets | 1,322 | 1,346 | 1,163 | 1,028 | 0 |
| Fixed Assets | 1,137 | 1,033 | 926 | 782 | 0 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 259 | 131 | 85 | 73 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 1,990 | 1,757 | 1,559 | 1,387 | 0 |
| Share Capital | 45 | 45 | 45 | 0 | 0 |
| Reserves & Surplus | 1,945 | 1,712 | 1,513 | 1,341 | 0 |
Aarti Pharma Labs Income Statement Screener - Profit & Revenue Analysis
Screen Aarti Pharma Labs income statement and profit fundamentals.
Analyze AARTIPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarti Pharma Labs share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 437 | 418 | 388 | 562 | 543 | 463 | 558 | 508 | 450 | 441 | 459 | 486 | 472 | 532 | 457 |
| Expenses | 333 | 344 | 293 | 418 | 409 | 364 | 459 | 388 | 353 | 352 | 374 | 405 | 385 | 441 | 371 |
| EBITDA | 104 | 74 | 95 | 144 | 134 | 98 | 99 | 120 | 97 | 89 | 85 | 81 | 87 | 91 | 86 |
| Operating Profit % | 23.00% | 18.00% | 24.00% | 26.00% | 24.00% | 20.00% | 17.00% | 23.00% | 21.00% | 20.00% | 19.00% | 16.00% | 18.00% | 17.00% | 19.00% |
| Depreciation | 29 | 25 | 23 | 23 | 23 | 21 | 20 | 19 | 19 | 18 | 17 | 16 | 16 | 17 | 14 |
| Interest | 13 | 11 | 7 | 7 | 10 | 6 | 5 | 5 | 5 | 4 | 4 | 6 | 5 | 6 | 4 |
| Profit Before Tax | 63 | 39 | 65 | 115 | 101 | 72 | 74 | 96 | 74 | 67 | 64 | 59 | 65 | 69 | 68 |
| Tax | 15 | 11 | 16 | 26 | 27 | 17 | 18 | 31 | 21 | 15 | 17 | 16 | 17 | 18 | 16 |
| Net Profit | 48 | 28 | 50 | 88 | 74 | 55 | 56 | 65 | 53 | 52 | 47 | 43 | 48 | 51 | 52 |
| EPS | 5.29 | 3.08 | 5.46 | 9.75 | 8.16 | 6.03 | 6.12 | 7.20 | 5.82 | 5.72 | 5.20 | 4.73 | 5.26 | 5.64 | 5.72 |
Aarti Pharma Labs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | 332 | 216 | 250 | -44 | 0 |
| Investing Activities | -414 | -215 | -158 | -139 | 0 |
| Financing Activities | 65 | 10 | -164 | 260 | 0 |
| Net Cash Flow | -17 | 12 | -71 | 78 | 0 |
Aarti Pharma Labs Shareholding Pattern Screener
See Aarti Pharma Labs shareholding pattern with promoter, FII, and DII holdings.
Check Aarti Pharma Labs promoter holding and ownership changes for AARTIPHARM on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 43.08% | 43.10% | 42.88% | 43.72% | 44.29% | 46.46% | 46.46% | 46.10% |
| FII Holding | 8.39% | 7.68% | 8.02% | 7.35% | 7.36% | 8.32% | 7.06% | 7.38% |
| DII Holding | 7.41% | 7.66% | 6.96% | 7.80% | 7.53% | 9.97% | 11.47% | 11.35% |
| Govt Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 34.29% | 34.85% | 35.39% | 34.43% | 34.10% | 29.71% | 29.57% | 29.45% |
| Other Holding | 6.82% | 6.70% | 6.74% | 6.69% | 6.71% | 5.52% | 5.43% | 5.71% |
| Shareholder Count | 179,373 | 184,489 | 190,655 | 187,039 | 196,314 | 204,122 | 189,012 | 185,436 |
Aarti Pharma Labs Share Dividend Screener - Share Yield Analysis
Check Aarti Pharma Labs dividend history with payout and yield data.
View Aarti Pharma Labs dividend details including ex-dates and amounts for AARTIPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.00 | 0.84% |
| 2024-March | ₹3.00 | 0.40% |
| 2023-March | ₹2.00 | 0.46% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Aarti Pharma Labs Stock Index Membership
See which indices include Aarti Pharma Labs stock.
Check AARTIPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Aarti Pharma Labs Market Events Screener - Corporate Actions
Get Aarti Pharma Labs corporate actions including splits, bonuses, and buybacks.
Check Aarti Pharma Labs stock events that may affect AARTIPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 2.50 /share | 20.75% | ||
| Annual General Meeting | NA | 9.96% | ||
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | -6.71% |
| 2026-02-16 | 2026-02-16 | Dividend | ₹ 1.50 /share | -8.80% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 2.01% |
| 2025-11-09 | 2025-11-09 | Quarterly Result Announcement | NA | 3.94% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -5.93% |
| 2025-05-10 | 2025-05-10 | Quarterly Result Announcement | NA | 1.74% |
| 2025-02-14 | 2025-02-14 | Dividend | ₹ 2.50 /share | 17.73% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 4.01% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -0.82% |
| 2024-08-07 | 2024-08-07 | Annual General Meeting | NA | -2.08% |
| 2024-07-31 | 2024-07-31 | Dividend | ₹ 1.00 /share | 22.39% |
| 2024-02-16 | 2024-02-19 | Dividend | ₹ 2.00 /share | -2.63% |
Aarti Pharma Labs Competitors Screener - Peer Comparison
Screen AARTIPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Aarti Pharma Labs Company Announcements - News Screener
Screen AARTIPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-16 | Update on board meeting | - |
| 2026-05-13 | Board Meeting Intimation for Approval Of The Audited Financial Results For The Quarter And Financial Year Ended March 31 2026 And Recommendation Of Final Dividend If Any. | - |
| 2026-04-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-04-04 | Intimation Regarding Second 100-Day Campaign - Saksham Niveshak | - |
| 2026-04-04 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-04 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-04 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-04 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-03-27 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-24 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-13 | Clarification Regarding Delay In Disclosure Of Event To The Exchange | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-10 | Corrigendum To Intimation Of Record Date For Dividend Dated February 09 2026. | - |
| 2026-02-10 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |